These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 27004444)
1. Clinical Impact of Heparin Kinetics During Catheter Ablation of Atrial Fibrillation: Meta-Analysis and Meta-Regression. Briceno DF; Villablanca PA; Lupercio F; Kargoli F; Jagannath A; Londono A; Patel J; Otusanya O; Brevik J; Maraboto C; Berardi C; Krumerman A; Palma E; Kim SG; Natale A; DI Biase L J Cardiovasc Electrophysiol; 2016 Jun; 27(6):683-93. PubMed ID: 27004444 [TBL] [Abstract][Full Text] [Related]
2. Management of Intraprocedural Anticoagulation in Patients on Non-Vitamin K Antagonist Oral Anticoagulants Undergoing Catheter Ablation for Atrial Fibrillation: Understanding the Gaps in Evidence. Martin AC; Godier A; Narayanan K; Smadja DM; Marijon E Circulation; 2018 Aug; 138(6):627-633. PubMed ID: 30354610 [TBL] [Abstract][Full Text] [Related]
3. Appropriate intraprocedural initial heparin dosing in patients undergoing catheter ablation for atrial fibrillation receiving uninterrupted non-vitamin-K antagonist oral anticoagulant treatment. Zhang RF; Ma CM; Wang N; Yang MH; Li WW; Yin XM; Dong YX; Yu XH; Xiao XJ; Xia YL; Gao LJ BMC Cardiovasc Disord; 2021 Apr; 21(1):214. PubMed ID: 33906609 [TBL] [Abstract][Full Text] [Related]
4. Catheter ablation of left atrial arrhythmias on uninterrupted oral anticoagulation with vitamin K antagonists: What is the relationship between international normalized ratio, activated clotting time, and procedure-related complications? Kottmaier M; Bourier F; Semmler V; Telishevska M; Koch-Büttner K; Lennerz C; Lengauer S; Kornmayer M; Rousseva E; Brooks S; Brkic A; Grebmer C; Kolb C; Hessling G; Deisenhofer I; Reents T J Cardiovasc Electrophysiol; 2017 Dec; 28(12):1415-1422. PubMed ID: 28800176 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of nonvitamin K antagonist oral anticoagulants during catheter ablation of atrial fibrillation: A systematic review and meta-analysis. Ge Z; Faggioni M; Baber U; Sartori S; Sorrentino S; Farhan S; Chandrasekhar J; Vogel B; Qadeer A; Halperin J; Reddy V; Dukkipati S; Dangas G; Mehran R Cardiovasc Ther; 2018 Oct; 36(5):e12457. PubMed ID: 29971964 [TBL] [Abstract][Full Text] [Related]
6. Influence of periprocedural anticoagulation strategies on complication rate and hospital stay in patients undergoing catheter ablation for persistent atrial fibrillation. Gunawardene M; Willems S; Schäffer B; Moser J; Akbulak RÖ; Jularic M; Eickholt C; Nührich J; Meyer C; Kuklik P; Sehner S; Czerner V; Hoffmann BA Clin Res Cardiol; 2017 Jan; 106(1):38-48. PubMed ID: 27435077 [TBL] [Abstract][Full Text] [Related]
7. Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants. Brinkmeier-Theofanopoulou M; Tzamalis P; Wehrkamp-Richter S; Radzewitz A; Merkel M; Schymik G; van Mark G; Bramlage P; Schmitt C; Luik A BMC Cardiovasc Disord; 2018 Apr; 18(1):71. PubMed ID: 29703158 [TBL] [Abstract][Full Text] [Related]
9. Continuous and minimally-interrupted direct oral anticoagulant are both safe compared with vitamin K antagonist for atrial fibrillation ablation: An updated meta-analysis. Ha FJ; Barra S; Brown AJ; Begley DA; Grace AA; Agarwal S Int J Cardiol; 2018 Jul; 262():51-56. PubMed ID: 29606512 [TBL] [Abstract][Full Text] [Related]
10. An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation. Cardoso R; Knijnik L; Bhonsale A; Miller J; Nasi G; Rivera M; Blumer V; Calkins H Heart Rhythm; 2018 Jan; 15(1):107-115. PubMed ID: 28917562 [TBL] [Abstract][Full Text] [Related]
11. Differences in activated clotting time among uninterrupted anticoagulants during the periprocedural period of atrial fibrillation ablation. Nagao T; Inden Y; Yanagisawa S; Kato H; Ishikawa S; Okumura S; Mizutani Y; Ito T; Yamamoto T; Yoshida N; Hirai M; Murohara T Heart Rhythm; 2015 Sep; 12(9):1972-8. PubMed ID: 25881495 [TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of safety and efficacy of oral anticoagulants in patients requiring catheter ablation for atrial fibrillation. Rahman H; Khan SU; DePersis M; Hammad T; Nasir F; Kaluski E Cardiovasc Revasc Med; 2019 Feb; 20(2):147-152. PubMed ID: 29786530 [TBL] [Abstract][Full Text] [Related]
13. Lower Major Bleeding Rates with Direct Oral Anticoagulants in Catheter Ablation of Atrial Fibrillation: an Updated Meta-analysis of Randomized Controlled Studies. Brunetti ND; Tricarico L; Tilz RR; Heeger CH; De Gennaro L; Correale M; Ieva R; Di Biase M; Rillig A; Metzner A; Santoro F Cardiovasc Drugs Ther; 2020 Apr; 34(2):209-214. PubMed ID: 32080786 [TBL] [Abstract][Full Text] [Related]
14. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. Di Biase L; Callans D; Hæusler KG; Hindricks G; Al-Khalidi H; Mont L; Cosedis Nielsen J; Piccini JP; Schotten U; Kirchhof P Europace; 2017 Jan; 19(1):132-138. PubMed ID: 28130378 [TBL] [Abstract][Full Text] [Related]
15. Periprocedural management of anticoagulation for atrial fibrillation catheter ablation in direct oral anticoagulant-treated patients. Martin AC; Lessire S; Leblanc I; Dincq AS; Philip I; Gouin-Thibault I; Godier A Clin Cardiol; 2018 May; 41(5):646-651. PubMed ID: 29532536 [TBL] [Abstract][Full Text] [Related]
16. Uninterrupted New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Ablation of Atrial Fibrillation: A Meta-analysis. Nairooz R; Ayoub K; Sardar P; Payne J; Almomani A; Pothineni NV; Shailesh F; Aronow WS; Mukherjee D Can J Cardiol; 2016 Jun; 32(6):814-23. PubMed ID: 26810476 [TBL] [Abstract][Full Text] [Related]
17. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort. Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY; Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063 [TBL] [Abstract][Full Text] [Related]
18. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. Caldeira D; Rodrigues FB; Barra M; Santos AT; de Abreu D; Gonçalves N; Pinto FJ; Ferreira JJ; Costa J Heart; 2015 Aug; 101(15):1204-11. PubMed ID: 26037103 [TBL] [Abstract][Full Text] [Related]
19. Effect of therapeutic INR on activated clotting times, heparin dosage, and bleeding risk during ablation of atrial fibrillation. Gautam S; John RM; Stevenson WG; Jain R; Epstein LM; Tedrow U; Koplan BA; McClennen S; Michaud GF J Cardiovasc Electrophysiol; 2011 Mar; 22(3):248-54. PubMed ID: 20812929 [TBL] [Abstract][Full Text] [Related]
20. Influence of the concomitant use of heparin on the effects of warfarin during catheter ablation for atrial fibrillation. Inada K; Matsuo S; Tokutake K; Yokoyama K; Hioki M; Narui R; Ito K; Tanigawa S; Yamashita S; Tokuda M; Shibayama K; Miyanaga S; Sugimoto K; Yoshimura M; Yamane T Heart Vessels; 2016 Mar; 31(3):397-401. PubMed ID: 25471944 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]